|
【参考文献】
1 Brady RO,Gal AE,Bradley RM. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Eng J Med 1967；276(21):11631167
2 Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004；34（3）:236242
3 Pastores GM, Lien YH. Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol2002；13 （Suppl 2）: S130133
4张苏华,尹广. Fabry 病及其酶替代疗法. 肾脏病与透析肾移植杂志 2004；13(6):560566
5 Peters FP,Vermeulen A,Kho TL. AndersonFabry’s disease: alpha galactosidase deficiency. Lancet 2001；357（9250）:138140
6 Font RL, Fine BS.Ocular pathology in fabry’s disease. Histochemical and electron microscopic observations. Am J Ophthalmol1972；73（3）:419430
7 Witschel H, Mathyl. Morphological bases of the specific ocular changes in Fabry’s disease. Klin Monatsbl Augenheilkd 1969；154（4）:599605
8 Whybra C, Kampmann C, Willers I, et al. AndersonFabry disease :clinical manifestations of disease in female heterozygotes. J Inherit metab Dis2001；24(7):715724
9 Farge D, Nadler S, Wolfe LS, et al. Diagnostic value of kidney biopsy in heterozygous Fabry’s disease. Arch Pathol Lab Med1985；109（1）:8588
10 Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry’s disease. Arch Ophthalmol 1979；97（4）:671676
11 Orssaud C, Dufier J, Germain D.Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 2003；24（3）:129139
12 Nguyen TT, Gin T, Nicholls K, et al. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol2005；33（2）:164168
13 Samiy N.Ocular Features of fabry disease: diagnosis of a treatable lifethreatening disorder. Surv Ophthalmol2008；53(4):416423
14 Spaeth GL, Frost P. Fabry’s disease. Its ocular manifestations. Arch Ophthalmol1965；74（6）:760769
15 Andersen MV, Dahl H, Fledelius H, et al. Central retinal artery occlusion in a patient with Fabrys disease documented by scanning laser ophthalmoscopy. Acta Ophthalmol（Copenh） 1994；72（5）:635638
16 Hirano K, Murata K, Miyagawa A, et al. Histopathologic findings of cornea verticillata in a woman heterozygous for Fabry’s disease. Cornea 2001；20(2):233236
17 Dantas MA, Fonseca RA, Kaga T, et al. Retinal and choroidal vascular changes in heterozygous Fabry disease. Retina 2001；21(11):8789
18 Oto S, Kart H, Kadayifcilar S, et al. Retinal vein occlusion in a woman with heterozygous Fabry’s disease. Eur J Ophthalmol1998；8(4):265267
19 Sher NA, Reiff W, Letson RD, et al. Central retinal artery occlusion complicating Fabry’s disease. Arch Ophthalmol1978；96(5):815817
20 Galanos J, Nicholls K, Grigg L, et al. Clinical features of Fabry’s disease in Australian patients. Intern Med J 2002；32(12):575584
21 MacDermot KD, Holmes A, Miners AH.AndersonFabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001；38(11):750760
22 Ries M, Moore DF, Robinson CJ, et al. Quantitative dysmorphology assessment in Fabry disease. Genet Med2006；8(2):96101
23 Alroy J ,Sabnis S ,Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol2002；13(Suppl 2):S134138
24 Sakuraba H ,Oshima A ,Fukuhara Y, et al. Identification of point mutations in the alpha galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet1990；47(5):784789
25 李秋芬，胡云琴，鲁盈. Fabry 病4例报道并文献复习.中国中西医结合肾病杂志2007；8(10):594595
26 Whybra C ,Kampmann C ,Willers I , et al. AndersonFabry disease:clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis2001；24(7) :715724
27 Deegan PB, Baehner AF, Barba Romero MA, et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006；43(4): 347352
28 Ramaswami U, Whybra C, Parini R, et al.FOS European Investigators. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006；95(1): 8692
29 Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease.baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007；30(2):184192
30 Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease.influence of alphagalactosidase A activity and genetic mutations on clinical course. Medicine(Baltimore)2002；81(27):122138
31 Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2007；2(7): e598
32 Linthorst GE, Hollak CE, DonkerKoopman WE, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004；66(4): 15891595
33 Sakuraba H, MurataOhsawa M, Kawashima I, et al. Comparison of the eff ects of agalsidase alfa and agalsidase beta on cultured human Fabry fi broblasts and Fabry mice. J Hum Genet 2006；51(3): 180188
34 Breunig F ,Weidemann F ,Beer M, et al. Fabry disease : diagnosis and treatment. kidney Int2003；63(Suppl 84):S181185
上一页 [1] [2] |
